IL-33 Aggravates DSS-Induced Acute Colitis in Mouse Colon Lamina Propria by Enhancing Th2 Cell Responses

Mediators of Inflammation

Volumn 2015, Issue , 2015, Pages

  Zhu, Junfeng ^a,b   Yang, Fangli ^a   Sang, Lixuan ^a   Zhai, Jingbo ^a   Zhang, Xiaoqing ^a   Yue, Dan ^a   Li, Shengjun ^a   Li, Yan ^a   Lu, Changlong ^a   Sun, Xun ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b LIAONING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DEXTRAN SULFATE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 33; INTERLEUKIN 4; INTERLEUKIN 5; RECOMBINANT CYTOKINE; RECOMBINANT INTERLEUKIN 33; RETINOID RELATED ORPHAN RECEPTOR GAMMA; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR T BET; UNCLASSIFIED DRUG; CYTOKINE; RECOMBINANT PROTEIN; TRANSCRIPTION FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEXTRAN SODIUM SULFATE-INDUCED COLITIS; DISEASE EXACERBATION; HISTOPATHOLOGY; INTRACELLULAR SIGNALING; LAMINA PROPRIA; MALE; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TH1 CELL; TH17 CELL; TH2 CELL; ACUTE DISEASE; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CHEMICALLY INDUCED; COLITIS; DRUG EFFECTS; IMMUNOLOGY;

MUS;

ACUTE DISEASE; ANIMALS; COLITIS; CYTOKINES; DEXTRAN SULFATE; INTERLEUKIN-33; MALE; MICE; MICE, INBRED C57BL; RECOMBINANT PROTEINS; TH2 CELLS; TRANSCRIPTION FACTORS;

EID: 84935871666     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2015/913041     Document Type: Article

References (52)

1. B. Khor, A. Gardet, and R. J. Xavier, "Genetics and pathogenesis of inflammatory bowel disease," Nature, vol. 474, no. 7351, pp. 307-317, 2011.
2. F. Scaldaferri and C. Fiocchi, "Inflammatory bowel disease: progress and current concepts of etiopathogenesis," Journal of Digestive Diseases, vol. 8, no. 4, pp. 171-178, 2007.
3. G. M. Cobrin and M. T. Abreu, "Defects in mucosal immunity leading toCrohns disease," Immunological Reviews, vol. 206, no. 1, pp. 277-295, 2005.
4. S. R. Targan and L. C. Karp, "Defects in mucosal immunity leading to ulcerative colitis," Immunological Reviews, vol. 206, pp. 296-305, 2005.
5. S. Fujino, A. Andoh, S. Bamba et al., "Increased expression of interleukin 17 in inflammatory bowel disease," Gut, vol. 52, no. 1, pp. 65-70, 2003.
6. C. T. Weaver, L. E. Harrington, P. R. Mangan, M. Gavrieli, and K. M. Murphy, "Th17: an effector CD4 T cell lineage with regulatory T cell ties," Immunity, vol. 24, no. 6, pp. 677-688, 2006.
7. C. O. Elson, R. B. Sartor, G. S. Tennyson, and R. H. Riddell, "Experimental models of inflammatory bowel disease," Gastroenterology, vol. 109, no. 4, pp. 1344-1367, 1995.
8. M. Perse and A. Cerar, "Dextran sodium sulphate colitis mouse model: traps and tricks," Journal of Biomedicine and Biotechnology, vol. 2012, Article ID 718617, 13 pages, 2012.
9. L. A. Dieleman, B. U. Ridwan, G. S. Tennyson, K. W. Beagley, R. P. Bucy, and C. O. Elson, "Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice," Gastroenterology, vol. 107, no. 6, pp. 1643-1652, 1994.
10. I. Okayasu, S. Hatakeyama, M. Yamada, T. Ohkusa, Y. Inagaki, and R. Nakaya, "A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice," Gastroenterology, vol. 98, no. 3, pp. 694-702, 1990.
11. M. Okamura, K. Yoh, M. Ojima, N. Morito, and S. Takahashi, "Overexpression of GATA-3 in T cells accelerates dextran sulfate sodium-induced colitis," Experimental Animals, vol. 63, no. 2, pp. 133-140, 2014.
12. J. Schmitz, A. Owyang, E. Oldhamet al., "IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines," Immunity, vol. 23, no. 5, pp. 479-490, 2005.
13. C. Moussion, N. Ortega, and J.-P. Girard, "The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel "Alarmin"?" PLoS ONE, vol. 3, no. 10, Article ID e3331, 2008.
14. E. S. Baekkevold, M. Roussign, T. Yamanaka et al., "Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules," The American Journal of Pathology, vol. 163, no. 1, pp. 69-79, 2003.
15. L. Pastorelli, C. de Salvo, M. A. Cominelli, M. Vecchi, and T. T. Pizarro, "Novel cytokine signaling pathways in inflammatory bowel disease: insight into the dichotomous functions of IL-33 during chronic intestinal inflammation," Therapeutic Advances in Gastroenterology, vol. 4, no. 5, pp. 311-323, 2011.
16. I. S. Wood, B. Wang, and P. Trayhurn, "IL-33, a recently identified interleukin-1 gene family member, is expressed in human adipocytes," Biochemical and Biophysical Research Communications, vol. 384, no. 1, pp. 105-109, 2009.
17. M. Lohning, A. Stroehmann, A. J. Coyle et al., "T1/ST2 is preferentially expressed onmurine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function," Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 12, pp. 6930-6935, 1998.
18. V. Trajkovic, M. J. Sweet, and D. Xu, "T1/ST2-an IL-1 receptorlike modulator of immune responses," Cytokine and Growth Factor Reviews, vol. 15, no. 2-3, pp. 87-95, 2004.
19. C. T. Fagundes, F. A. Amaral, A. L. S. Souza et al., "ST2, an IL-1R family member, attenuates inflammation and lethality after intestinal ischemia and reperfusion," Journal of Leukocyte Biology, vol. 81, no. 2, pp. 492-499, 2007.
20. H. Hayakawa, M. Hayakawa, A. Kume, and S.-I. Tominaga, "Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation," Journal of Biological Chemistry, vol. 282, no. 36, pp. 26369-26380, 2007.
21. M. Komai-Koma, D. Xu, Y. Li, A. N. J. McKenzie, I. B. McInnes, and F. Y. Liew, "IL-33 is a chemoattractant for human Th2 cells," European Journal of Immunology, vol. 37, no. 10, pp. 2779-2786, 2007.
22. M. A. Rank, T. Kobayashi, H. Kozaki, K. R. Bartemes, D. L. Squillace, and H. Kita, "IL-33-activated dendritic cells induce an atypical TH2-type response," Journal of Allergy and Clinical Immunology, vol. 123, no. 5, pp. 1047-1054, 2009.
23. J. B. Seidelin, J. T. Bjerrum, M. Coskun, B. Widjaya, B. Vainer, and O. H. Nielsen, "IL-33 is upregulated in colonocytes of ulcerative colitis," Immunology Letters, vol. 128, no. 1, pp. 80-85, 2010.
24. A. Kobori, Y. Yagi, H. Imaeda et al., "Interleukin-33 expression is specifically enhanced in inflamed mucosa of ulcerative colitis," Journal of Gastroenterology, vol. 45, no. 10, pp. 999-1007, 2010.
25. P. Groß K. Doser, W. Falk, F. Obermeier, and C. Hofmann, "IL-33 attenuates development and perpetuation of chronic intestinal inflammation," Inflammatory Bowel Diseases, vol. 18, no. 10, pp. 1900-1909, 2012.
26. M. A. K. Sedhom, M. Pichery, J. R. Murdoch et al., "Neutralisation of the interleukin-33/ST2 pathway ameliorates experimental colitis through enhancement of mucosal healing In mice," Gut, vol. 62, no. 12, pp. 1714-1723, 2013.
27. P. N. Pushparaj, D. Li, M. Komai-Koma et al., "Interleukin-33 exacerbates acute colitis via interleukin-4 in mice," Immunology, vol. 140, no. 1, pp. 70-77, 2013.
28. H. Imaeda, A. Andoh, T. Aomatsu et al., "Interleukin-33 suppresses Notch ligand expression and prevents goblet cell depletion in dextran sulfate sodium-induced colitis," International Journal of Molecular Medicine, vol. 28, no. 4, pp. 573-578, 2011.
29. K. Oboki, T. Ohno, N. Kajiwara et al., "IL-33 is a crucial amplifier of innate rather than acquired immunity," Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 43, pp. 18581-18586, 2010.
30. L. H. Duan, J. Chen, H. W. Zhang et al., "Interleukin-33 ameliorates experimental colitis through promoting Th2/Foxp3+ regulatory T-cell responses in mice," Molecular Medicine, vol. 18, no. 5, pp. 753-761, 2012.
31. H. S. Cooper, S. N. S. Murthy, R. S. Shah, and D. J. Sedergran, "Clinicopathologic study of dextran sulfate sodiumexperimental murine colitis," Laboratory Investigation, vol. 69, no. 2, pp. 238-249, 1993.
32. X. Sun, S. Somada, K. Shibata et al., "A critical role of CD30 ligand/CD30 in controlling inflammatory bowel diseases in mice," Gastroenterology, vol. 134, no. 2, pp. 447-458, 2008.
33. L. A. Dieleman, M. J. H. J. Palmen, H. Akol et al., "Chronic experimental colitis induced by dextran sulphate sodium(DSS) is characterized by Th1 and Th2 cytokines," Clinical and Experimental Immunology, vol. 114, no. 3, pp. 385-391, 1998.
34. M. F. Neurath, S. Finotto, and L. H. Glimcher, "The role of Th1/Th2 polarization in mucosal immunit," Nature Medicine, vol. 8, no. 6, pp. 567-573, 2002.
35. D. K. Podolsky, "Inflammatory bowel disease,"TheNew England Journal of Medicine, vol. 347, no. 6, pp. 417-429, 2002.
36. I. J. Fuss, F. Heller, M. Boirivant et al., "Nonclassical CD1drestricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis," The Journal of Clinical Investigation, vol. 113, no. 10, pp. 1490-1497, 2004.
37. F. Heller, P. Florian, C. Bojarski et al., "Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution," Gastroenterology, vol. 129, no. 2, pp. 550-564, 2005.
38. J. B. Seidelin, M. Coskun, P. H. Kvist, T. L. Holm, K. Holgersen, and O. H. Nielsen, "IL-33 promotesGATA-3 polarization of gutderived T cells in experimental and ulcerative colitis," Journal of Gastroenterology, vol. 50, no. 2, pp. 180-190, 2015.
39. M. Kurowska-Stolarska, P. Kewin, G. Murphy et al., "IL-33 induces antigen-specific IL-5+ T cells and promotes allergicinduced airway inflammation independent of IL-4," The Journal of Immunology, vol. 181, no. 7, pp. 4780-4790, 2008.
40. W. B. Cherry, J. Yoon, K. R. Bartemes, K. Iijima, and H. Kita, "A novel IL-1 family cytokine, IL-33, potently activates human eosinophils," The Journal of Allergy and Clinical Immunology, vol. 121, no. 6, pp. 1484-1490, 2008.
41. M. Suzukawa, M. Iikura, R. Koketsu et al., "An IL-1 cytokine member, IL-33, induces human basophil activation via its ST2 receptor," The Journal of Immunology, vol. 181, no. 9, pp. 5981-5989, 2008.
42. M. Kurowska-Stolarska, B. Stolarski, P. Kewin et al., "IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation," The Journal of Immunology, vol. 183, no. 10, pp. 6469-6477, 2009.
43. J. C. Alves-Filho, F. Snego, F. O. Souto et al., "Interleukin-33 attenuates sepsis by enhancing neutrophil influx to the site of infection," Nature Medicine, vol. 16, no. 6, pp. 708-712, 2010.
44. K. R. Bartemes, K. Iijima, T. Kobayashi, G. M. Kephart, A. N. McKenzie, and H. Kita, "IL-33-responsive lineage-CD25+ CD44(hi) lymphoid cells mediate innate type 2 immunity and allergic inflammation in the lungs," The Journal of Immunology, vol. 188, no. 3, pp. 1503-1513, 2012.
45. J. Mjosberg, J. Bernink, K. Golebski et al., "The transcription factor GATA3 is essential for the function of human Type 2 innate lymphoid cells," Immunity, vol. 37, no. 4, pp. 649-659, 2012.
46. T. Hoyler, C. S. N. Klose, A. Souabni et al., "The transcription factor GATA-3 controls cell fate and maintenance of type 2 innate lymphoid cells," Immunity, vol. 37, no. 4, pp. 634-648, 2012.
47. D. R. Neill, S. H. Wong, A. Bellosi et al., "Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity," Nature, vol. 464, no. 7293, pp. 1367-1370, 2010.
48. F. Obermeier, G. Kojouharoff, W. Hans, J. Scholmerich, V. Gross, and W. Falk, "Interferon-gamma (IFN-γ)-and tumour necrosis factor (TNF)-induced nitric oxide as toxic effector molecule in chronic dextran sulphate sodium (DSS)-induced colitis in mice," Clinical and Experimental Immunology, vol. 116, no. 2, pp. 238-245, 1999.
49. M. Leppkes, C. Becker, I. I. Ivanov et al., "RORγ-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F," Gastroenterology, vol. 136, no. 1, pp. 257-267, 2009.
50. F. Sanchez-Munoz, A. Dominguez-Lopez, and J. K. Yamamoto-Furusho, "Role of cytokines in inflammatory bowel disease," World Journal ofGastroenterology, vol. 14, no. 27, pp. 4280-4288, 2008.
51. H.-R. Jiang, M. Milovanovic, D. Allan et al., "IL-33 attenuates EAE by suppressing IL-17 and IFN-γ production and inducing alternatively activated macrophages," European Journal of Immunology, vol. 42, no. 7, pp. 1804-1814, 2012.
52. M. Barbour, D. Allan, H. Xu et al., "IL-33 attenuates the development of experimental autoimmune uveitis," European Journal of Immunology, vol. 44, no. 11, pp. 3320-3329, 2014.